August 8, 2023 | San Antonio, TX
LumaBridge today announced the appointment of Amanda Ferrier as Chief Operating Officer.
August 8, 2023 | San Antonio, TX
LumaBridge today announced the appointment of Amanda Ferrier as Chief Operating Officer.
May 31, 2023 | San Antonio, TX
LumaBridge today announced the appointment of Todd Lehman as Vice President and Head of Business Development.
August 24, 2022 | San Francisco, CA & San Antonio, TX
LumaBridge and the Parker Institute for Cancer Immunotherapy (PICI) have announced a new strategic partnership aimed at accelerating breakthrough immunotherapies with greater ease.
August 23, 2022 | San Antonio, TX
Cancer Insight today introduced a new corporate identity: LumaBridge. As LumaBridge, the company will continue to build on its legacy of supporting the development of novel immunotherapies in the fight against cancer.
August 23, 2022 | Boston, MA & San Antonio, TX
LumaBridge today announced a majority growth investment from global investor Summit Partners. The funding will help LumaBridge continue to build on its work offering best-in-class clinical trial solutions to support emerging biopharma companies.